Get access to our best features
Get access to our best features
Published 2 months ago

Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

Summary by Medical Xpress
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine. By providing whole-body quantification of HER2 expression, 68Ga-ABY-025 PET/CT can play a valuable role in treatment planning and could spare patients from unnecessary drug-related si…

Bias Distribution

  • 100% of the sources are Center
100% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics